Compare
Sight Sciences, Inc. vs PRO DEX Inc vs AVITA Medical, Inc. vs Iradimed Corp
| Latest fiscal year | Sight Sciences, Inc. SGHT | PRO DEX Inc PDEX | AVITA Medical, Inc. RCEL | Iradimed Corp IRMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $77.36M | $77.55M | $71.61M | $83.81M |
| Revenue growth (YoY) | -3.1% | +16.5% | +11.5% | +14.4% |
| Gross margin | 86.2% | 31.4% | 82.1% | 76.7% |
| Operating margin | -48.0% | 16.8% | -59.4% | 31.2% |
| Net margin | -49.7% | 17.6% | -67.8% | 26.8% |
| Net income | -$38.43M | $13.66M | -$48.59M | $22.48M |
| EPS (Diluted) | -$0.74 | $4.12 | -$1.74 | $1.75 |
| Operating cash flow | -$29.69M | $7.24M | -$31.20M | $24.95M |
| Free cash flow | -$29.92M | $6.76M | -$32.20M | $17.18M |
| Cash & equivalents | $91.97M | $8.19M | $10.24M | $51.16M |
| Total assets | $115.30M | $74.51M | $56.39M | $108.78M |
| Total liabilities | $51.36M | $26.88M | $73.04M | $14.16M |
| Shareholders' equity | $63.94M | $47.63M | -$16.65M | $94.62M |
| Return on year-end equity | -60.1% | 28.7% | n/a | 23.8% |
| Shares outstanding | 53.49M | 3.19M | 30.57M | 12.78M |
Revenue, most recent five fiscal years
| Fiscal year | Sight Sciences, Inc. | PRO DEX Inc | AVITA Medical, Inc. | Iradimed Corp |
|---|---|---|---|---|
| Latest | $77.36M Ended 2025-12-31 | $77.55M Ended 2026-06-30 | $71.61M Ended 2025-12-31 | $83.81M Ended 2025-12-31 |
| 1 year earlier | $79.87M Ended 2024-12-31 | $66.59M Ended 2025-06-30 | $64.25M Ended 2024-12-31 | $73.24M Ended 2024-12-31 |
| 2 years earlier | $81.06M Ended 2023-12-31 | $53.84M Ended 2024-06-30 | $50.14M Ended 2023-12-31 | $65.56M Ended 2023-12-31 |
| 3 years earlier | $71.33M Ended 2022-12-31 | $46.09M Ended 2023-06-30 | $34.42M Ended 2022-12-31 | $53.30M Ended 2022-12-31 |
| 4 years earlier | $48.96M Ended 2021-12-31 | $42.04M Ended 2022-06-30 | n/a | $41.81M Ended 2021-12-31 |